Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

Christophe Le Tourneau,Valentin Calugaru,Zoltán Takácsi-Nagy,Xavier Liem,Zsuzsanna Papai,Jacek Fijuth,Victor Moreno,Jordi Giralt,Sébastien Salas,Gilles Poissonnet,Emiliano Calvo,Bernard Doger,Olivier Choussy,Xavier Mirabel,Samar Krhili,K. Bernois,Nicolas Fakhry,Stéphanie Wong Hee Kam,Edith Borcoman,Caroline Hoffmann

Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

2021

6051Background: The non-surgical standard of care (SOC) for the treatment of locally advanced head and neck squamous cell carcinoma (LA HNSCC) patients is concurrent chemoradiation with high dose c...

Keywords:

Head and neck squamous-cell carcinoma
locally advanced
Hafnium oxide
Medicine
standard of care
Oncology
Internal medicine
phase i study
Radiation therapy
Cisplatin
concurrent chemoradiation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations